Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IMCR
- Price
- 30.13
- Stock movement up
- +0.66 (2.24%)
- Company name
- Immunocore Holdings Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 1.51B
- Ent værdi
- 1.68B
- Pris/omsætning
- 4.54
- Pris/bog
- 3.99
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- 237.05%
- 1 års afkast
- -51.81%
- 3 års afkast
- 0.45%
- 5 års afkast
- -
- 10 års afkast
- -
Senest opdateret: 2025-03-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UDBYTTE
IMCR betaler ikke udbytte
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | 51.68 |
| Pris til FCF | 51.32 |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 4.54 |
| Pris til egenkapital | 3.99 |
| EV i forhold til salg | 5.05 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 50.03M |
| EPS (TTM) | -1.02 |
| FCF pr. aktie (TTM) | 0.56 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 331.79M |
| Bruttofortjeneste (TTM) | 329.63M |
| Driftsindkomst (TTM) | -76.80M |
| Nettoindkomst (TTM) | -53.73M |
| EPS (TTM) | -1.02 |
| EPS (1 år frem) | -1.19 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 99.35% |
| Driftsmargin (TTM) | -23.15% |
| Fortjenstmargin (TTM) | -16.20% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 537.77M |
| Nettotilgodehavender | 63.66M |
| Omsætningsaktiver i alt | 1.01B |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 1.08B |
| Kreditor | 19.72M |
| Kortfristet/nuværende langsigtet gæld | 481.06M |
| Summen af kortfristede forpligtelser | 266.25M |
| Sum gæld | 706.81M |
| Aktionærernes egenkapital | 377.83M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 29.17M |
| Investeringsudgifter (TTM) | 2.18M |
| Fri pengestrøm (TTM) | 29.37M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -14.22% |
| Afkast af aktiver | -4.95% |
| Afkast af investeret kapital | -12.58% |
| Kontant afkast af investeret kapital | 6.88% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 29.03 |
| Daglig høj | 30.34 |
| Daglig lav | 28.92 |
| Daglig volumen | 555K |
| Højeste gennem alle tider | 75.36 |
| 1 års analytiker estimat | 63.59 |
| Beta | 0.72 |
| EPS (TTM) | -1.02 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 6 May 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| IMCR | S&P500 | |
| Nuværende prisfald fra top notering | -60.02% | -7.48% |
| Højeste prisfald | -66.38% | -56.47% |
| Højeste efterår dato | 20 Jan 2022 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -30.78% | -11.07% |
| Gennemsnitlig tid til nyt højdepunkt | 58 days | 12 days |
| Maks. tid til nyt højdepunkt | 399 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
1.51B
Markedsværdi kategori
Small-cap
Beskrivelse
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Personale
497
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
USA
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Seeking AlphaPressemeddelelser
Immunocore Holdings is a promising biotech investment in 2024 with leading products and potential takeover appeal. See why IMCR stock is a Buy.
12. august 2024
iO Charts is a Seeking Alpha partnerNæste side